Across TCGA pan-cancer cohorts, NOMO2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NOMO2 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher NOMO2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NOMO2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, BLCA, and CESC are the cancer types where NOMO2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.514	0.963	<.001	34	view →
BLCA	OS	Median	All	0.193	0.720	.004	21	view →
CESC	DFS	Median	All	0.080	0.543	.013	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.443	.033	10	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: NOMO2 tumor-vs-normal RNA expression · all NOMO2 data types